Teva Branded Pharmaceutical Products R&D, Inc. Sustainability Profile
Teva Branded Pharmaceutical Products R&D, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is a leading player in the global pharmaceutical industry, headquartered in the United States. Founded in 1901, Teva has established itself as a pioneer in the development and manufacturing of generic and specialty medicines, with a strong focus on therapeutic areas such as central nervous system disorders, respiratory conditions, and oncology. With major operational regions across North America, Europe, and beyond, Teva is renowned for its extensive portfolio of high-quality medications. The company’s commitment to innovation is evident in its robust research and development efforts, which have led to numerous key milestones, including the launch of several groundbreaking treatments. Teva's unique approach to drug development and its market position as one of the largest generic drug manufacturers underscore its significant contributions to improving patient outcomes worldwide.
DitchCarbon Score
How does Teva Branded Pharmaceutical Products R&D, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Teva Branded Pharmaceutical Products R&D, Inc.'s score of 82 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Teva Branded Pharmaceutical Products R&D, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Teva Pharmaceutical Industries Limited, any climate commitments or emissions data would be inherited from this parent organisation. Teva Pharmaceutical Industries Limited has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for Teva Branded Pharmaceutical Products R&D, Inc. have not been detailed. As part of its corporate family, Teva Branded Pharmaceutical Products R&D, Inc. aligns with the broader sustainability goals of its parent company, which may include commitments to reduce greenhouse gas emissions across all scopes. Nonetheless, without specific emissions data or reduction targets available for this subsidiary, a comprehensive overview of its carbon footprint and climate commitments remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Teva Branded Pharmaceutical Products R&D, Inc.'s Industry?
How Carbon Intensive is Teva Branded Pharmaceutical Products R&D, Inc.'s Location?
Teva Branded Pharmaceutical Products R&D, Inc.'s Scope 3 Categories Breakdown
Teva Branded Pharmaceutical Products R&D, Inc.'s Scope 3 emissions, which decreased by 6% last year and decreased by approximately 24% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 61% of Scope 3 emissions.
Top Scope 3 Categories
Teva Branded Pharmaceutical Products R&D, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Teva Branded Pharmaceutical Products R&D, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
